XDWL:F:F-db x-trackers MSCI World UCITS DR 1D (EUR)

ETF | Others |

Last Closing

USD 88.644

Change

-0.05 (-0.06)%

Market Cap

USD 1.13B

Volume

2.18K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.08 (-0.28%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.28 (+0.24%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.17 (-0.32%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.19 (+0.19%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.08 (-0.08%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.03 (-0.35%)

USD 40.38B
0ZC:F Zscaler Inc

-2.26 (-1.45%)

USD 37.92B

ETFs Containing XDWL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.70% 75% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.70% 72% C 62% D
Trailing 12 Months  
Capital Gain 21.22% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.22% 70% C- 62% D
Trailing 5 Years  
Capital Gain 65.08% 81% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.08% 81% B- 64% D
Average Annual (5 Year Horizon)  
Capital Gain 11.67% 79% B- 73% C
Dividend Return 11.67% 77% C+ 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.56% 50% F 80% B-
Risk Adjusted Return 86.06% 92% A 93% A
Market Capitalization 1.13B 74% C 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike